Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1479-828X.2010.01249.x | DOI Listing |
J Immunother Cancer
January 2025
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Background: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.
Methods: Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression.
BMC Complement Med Ther
December 2024
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: A precise observation is that the cervix's solid tumors possess hypoxic regions where the oxygen concentration drops below 1.5%. Hypoxia negatively impacts the host's immune system and significantly diminishes the effectiveness of several treatments, including radiotherapy and chemotherapy.
View Article and Find Full Text PDFAdv Anat Pathol
January 2025
Department of Pathology, University of Michigan-Michigan Medicine, Ann Arbor, MI.
Uterine smooth muscle neoplasms are a biologically and clinically heterogeneous group of tumors. Morphology is the cornerstone of pathologic diagnosis of these tumors, and most are readily classified as benign or malignant on the basis of routine histologic examination. However, rare subsets-including intravenous leiomyomatosis, benign metastasizing leiomyoma, and disseminated peritoneal leiomyomatosis-have a capacity for extrauterine spread despite benign cytomorphology.
View Article and Find Full Text PDFCureus
November 2024
Obstetrics and Gynecology, Gunma University Hospital, Maebashi, JPN.
Objective: This study aims to investigate the efficacy of continuous oxytocin administration after completion of routine oxytocin administration during the third stage of labor in patients with twin pregnancies delivered via cesarean delivery (CD).
Methods: This retrospective case-control study was conducted between April 2014 and March 2024, and it included 156 women with twin pregnancies. The oxytocin group included patients who were administered continuous oxytocin 2 IU/h until 24 hours after delivery after completion of oxytocin 5 IU intravenous injection immediately after delivery as the routine procedure.
Cureus
November 2024
Internal Medicine, Dubai Medical College for Girls, Dubai, ARE.
A pregnant woman was brought to the emergency department looking starved and neglected. She was diagnosed with sepsis and started on intravenous antibiotics. She was also disoriented and hypernatremic.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!